CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, signed a marketing and distribution agreement with STADA Arzneimittel AG.
STADA will market and distribute two EMA-approved biosimilars developed by CuraTeQ in select EU territories including France and Germany.
New brand names will be created for each biosimilar; the deal is classified as non-material under SEBI Regulation 30(4).